Oramed Pharmaceuticals Inc. — Form 10-Q Summary
Business context and period: This unaudited quarterly report covers the three months ended November 30, 2014, Oramed’s fiscal first quarter of 2015. Oramed is a clinical-stage pharmaceutical company developing oral insulin and other orally delivered peptide products. It reported no operating revenue.
Financial performance and position
- Results (USD thousands): Research and development expense, net, was $1,302, up 74% from $750 a year earlier. General and administrative expense was $600, up 44% from $418. Operating loss was $1,902 versus $1,168; net loss was $1,896 versus $1,124. Basic and diluted loss per share was $0.19 versus $0.14.
- Cash flow: Operating activities used $1,399, compared with $748 used in the prior-year quarter. Investing activities provided $1,476, mainly from short-term deposit maturities; financing activities provided $4,833 net from a common-stock issuance. Cash and cash equivalents increased to $6,656 from $1,762 at August 31, 2014.
- Liquidity: At November 30, current assets were $24,533 and current liabilities were $827, for working capital of $23,706. Cash, short-term deposits and marketable securities totaled $24,370. Management estimated $9,853 of planned expenditures for the following 12 months.
- Debt and margins: No borrowings or interest-bearing debt are reported in the provided filing text. Margins are not meaningful because the company had no revenue.
- Other comprehensive loss: Total comprehensive loss was $2,255, including $350 of unrealized losses on available-for-sale securities, principally D.N.A Biomedical Solutions shares. The company held approximately 9.8% of D.N.A at quarter-end.
Material changes versus the prior comparable quarter
- Net loss increased by $772, or approximately 69%, as R&D and G&A costs rose. Management attributed higher R&D spending primarily to preparation for the ORMD-0801 Phase IIb trial; higher G&A was mainly associated with increased stock-based compensation.
- Net financial income declined to $6 from $44, mainly because of increased foreign-exchange expense.
- The November 2014 private placement generated approximately $5,000 gross and $4,833 net, with 696,378 shares sold at $7.18 each. Shares issued and outstanding rose to 10,812,471 from 10,102,555 at August 31.
Outlook, risks, and notable items
- Management expected current resources and commitments to support planned development and spending for at least the next 12 months, while noting that unexpected cost increases could require additional financing. The company anticipates approximately $9.9 million in expenditures over that period: $7.525 million for net R&D and $2.328 million for G&A.
- Oramed expected to begin the ORMD-0801 Phase IIb trial for type 2 diabetes in the first quarter of calendar 2015, with results anticipated before year-end 2015. The planned trial was approximately 180 patients at about 30 U.S. sites. A Phase IIa study in type 1 diabetes was completed; the company reported a safety and tolerability signal and exploratory trends, but said the study was not powered for statistical significance.
- For oral exenatide candidate ORMD-0901, preclinical studies began in November 2014. The company expected non-U.S. Phase Ib trials and IND-enabling studies to begin in the second quarter of calendar 2015, followed by an intended U.S. IND and Phase II program.
- A CRO agreement for the planned Phase IIb study provides for approximately $3.290 million in milestone-based payments; $595,000 had been recognized by quarter-end. The company also disclosed manufacturing and development commitments, including a subsequent December 2014 agreement for $550,000 payable on milestones.
- Key risks include clinical and regulatory uncertainty, the possibility that candidates will not receive approval, and the need for continued financing. The company had accumulated losses of $29.716 million. It reported no material off-balance-sheet arrangements and no significant change in market-risk exposure.
Important facts for investors to verify
- Whether the planned ORMD-0801 Phase IIb trial began on schedule and whether its results supported further development.
- Whether ORMD-0901 studies and regulatory steps proceeded as planned.
- Cash burn, milestone commitments, and financing needs relative to the stated 12-month expenditure plan and management’s liquidity assessment.
- Changes in the value of the D.N.A Biomedical investment and the effect of marketable-security losses on reported comprehensive income.
- Timing and terms of any subsequent financing, government grants, or material clinical and regulatory developments.